Analyzing GlucoTrack (NASDAQ:GCTK) & Cytosorbents (NASDAQ:CTSO)

GlucoTrack (NASDAQ:GCTK) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares GlucoTrack and Cytosorbents’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-826.43%	-707.26%
Cytosorbents	-49.47%	-118.54%	-42.31%

Institutional and Insider Ownership

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 46.5% of GlucoTrack shares are held by company insiders. Comparatively, 6.6% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares GlucoTrack and Cytosorbents”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$7.10 million	($56.60)	-0.01
Cytosorbents	$33.79 million	1.73	-$28.51 million	($0.36)	-2.97

GlucoTrack has higher earnings, but lower revenue than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

GlucoTrack has a beta of -0.29, indicating that its share price is 129% less volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for GlucoTrack and Cytosorbents, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	0	0	0	0	0.00
Cytosorbents	0	1	2	1	3.00

Cytosorbents has a consensus target price of $4.67, indicating a potential upside of 336.14%. Given Cytosorbents’ stronger consensus rating and higher probable upside, analysts plainly believe Cytosorbents is more favorable than GlucoTrack.

Summary

Cytosorbents beats GlucoTrack on 10 of the 14 factors compared between the two stocks.

About GlucoTrack

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.